Aytu Biopharma, Inc. · NASDAQ:AYTU
Aytu Biopharma — Investor Presentation (June 2025)
33 slides from Aytu Biopharma's investor presentation, Jun 17, 2025
Slide 1: Aytu BioPharma June 2025
u BIOPHARMA yA Nasdaq: AYTU JUNE 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘This presentation includes forward-ooking statements within the meaning of Section 27A ofthe Secures Ac of 1933, as amended (Secures Act), nd Section 21E ofthe Securities Exchange Act of 1334, as amended (Exchange Act Al siaterents other than statements of historical fact
Slide 3: Medicines Made for Life
3 @&Aytu BIOPHARMA Medicines Made for Life. The mission of Aytu BioPharma is to improve the lives of patients everywhere, with a distinct focus on complex CNS conditions. Our novel therapeutics enhance the lives of patients living with major depressive disorder (MDD) and attention deficit/hyperactiv
Slide 4: Successful Multi-Year Strategic Realignment Completed
4 Successful Multi-Year Strategic Realignment to Focus Company on Profitable Prescription Pharmaceutical Business Completed $36 million adjusted EBITDA improvement over three-year period Se ss October 2022 - Indefinite Suspension of Clinical “s10) June 2024 - Paydown and Refinancing of Term Loan on
Slide 5: Diversification & Growth Through Strategic Business Development
Diversification & Growth Through Strategic Business Development Leverage experience of a portfolio built through efficient M&A to add accretive, novel, branded prescription products to commercial portfolio HISTORY OF SUCCESSFUL PRODUCT ACQUISITIONS IN-LICENSE/ACQUISITION OF ESTABLISHED RX BRANDS Lau
Slide 6: Novel, Patent-Protected Prescription Portfolio
Novel, Patent-Protected Prescription Portfolio Differentiated Rx brands primarily focused on CNS conditions IP-PROTECTED MDD BRAND IP-PROTECTED ADHD BRANDS IP-PROTECTED PEDIATRIC BRANDS Commercial launch expected In Calendar Q4 3025, + EXKUA specifically targets pathophysiology of MDD through a uniq
Slide 7: Rx Revenue
Rx Revenue ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) revenue increased 23% in fiscal 2024 to $57.8 million versus $46.9 million in fiscal 2023. The Company expects revenue growth across the Rx business. RX REVENUE BY PORTFOLIO 0) ‘0 sora 0 EXXUA for MDD poised to $029 launch in fourth qu
Slide 8: Aytu RxConnect Patient Access Program
Aytu RxConnect Patient Access Program Aytu RxConnect is a proprietary, best-in-class patient access program, supported by an efficient commercial infrastructure, that enables affordable, predictable, hassle-free patient access to Aytu Rx products. Developed in-house to drive patient adherence and in
Slide 9: Aytu RxConnect Creates Rx Stickiness
Aytu RxConnect Creates Rx “Stickiness” The Aytu RxComnect platform delivers value for patients, prescribers, and Aytu >85% of Aytu’s core brands are dispensed through Aytu RxComect partner pharmacies % Core Products TRx through Aytu RxConnect Pharmac! How Aytu RxConnect Delivers Value for Patients &
Slide 10: Broad Commercial Infrastructure
Broad Commercial Infrastructure Efficient, leverageable commercial infrastructure for Rx Portfolio through 40 internal commercial representatives allows for easily scalable product expansion opportunities © Lean, direct sales force covers approximately 60% of MDD writers in our current geography and
Slide 11: New Development: The EXXUA Opportunity
Slide 12: EXXUA (gepirone) Extended-Release Tablets
EXXUA (gepirone) Extended-Release Tablets A first- antidepressants 4 Major Competitive ‘Advantage Demonstrated efcicy XXL specifica ond Ineeating MOS ne, cirecty targets Wwel-cotroedcinial —_pathophyailagy of. tras and five MOD through a novel _altional supportive MOR Welt studies while avoiing char
Slide 13: Significant Unmet Needs Exist in MDD
Significant Unmet Needs Exist in MDD EXXUA provides an important new treatment option for MDD patients seeking an effective therapy without inducing side effects like TESD & weight gain + Major Depressive Disorder affects more than 20 million people in the United States, creating a $22B+ Rx therapeu
Slide 14: EXXUA: A Clear Position in the MDD Market
EXXUA: A Clear Position in the MDD Market EXXUA has a unique profile due to its MOA which helps explain the lack of impact on sexual function or weight - key issues for many MDD patients 9/90|\0\/ 0/0 8 9990000 e699 0080 ‘exxug
Slide 15: EXXUA Potential Sources of Patients
EXXUA Potential Sources of Patients* >1 Mil 2N0 LINE THERAPY 2N OR 3° LINE THERAPY [iM 30 OR 4™H LINE THERAPY 4™ LINE THERAPY + ion TRxs / Year with Minimal Market Penetration Commonly Prescribed SSRIs. ‘Buproprion Trintellix or Auvelity All Others | | ! 297K es 442M Res aos aBTK Res 622M es 20758 M
Slide 16: Significant Revenue Potential for EXXUA
Significant Revenue Potential for EXXUA Recent branded psychiatric product launches support significant revenue potential for an MDD therapeutic with a unique MOA CAPLYTAY: oer ete. mawicts acts mane emo samen sone rm — — aa ‘exnaian sumo eons sa swe sm ase sume seme ] oy — 16 @Aytu Sexxua
Slide 17: EXXUA Market Research - Lumanity
EXXUA Market Research = Lumanity Lumanity conducted robust market research and develop corresponding forecast scenarios supporting the significant market potential for EXXUA “I would definitely try it in folks where everything else has failed because the mechanism is very different” “Notall patients
Slide 18: Sales Force Well Aligned to Psychiatry
Sales Force Well Aligned to Psychiatry Given Aytu BioPharma’s current focus on ADHD/psychiatry, we are already well aligned with EXXUA potential through Aytu’s sales force and call points. ‘Recent MDD Brands* Tx + 6.4k Psychiatrists targeted by Aytu sales force since beginning of 2024 The company an
Slide 19: EXXUA Promotional Mix & Commercial Priorities
EXXUA Promotional Mix & Commercial Priorities COMMERCIAL LAUNCH FOCUS + Efficient, multi-faceted launch with emphasis on sales force promation and metrcs-based performance management + Personal selling augmented by cost-effective Medical Afaits-led publication and KOL support + Broadened retail dist
Slide 20: ADHD & Pediatrics
Slide 21: Strong TRx Growth Across ADHD Portfolio
a Strong TRx Growth Across ADHD Portfolio From FY21 to FY24, total prescriptions written monthly for ADHD product portfolio steadily grew Pediatric net revenue rebounded, with 77% growth from Q325 compared to Q324 ADHD Portfolio (TRxs) Pediatric Portfolio (TRxs) Combined (TRxs) 450.00 250,000 soto o
Slide 22: Global Footprint Expansion Through Out-Licensing of ADHD Brands
Global Footprint Expansion Through Out-Licensing of ADHD Brands Ex-U.S. royalty revenue coming from ADHD brands in Canada & Israel with additional territories under discussion ~$1B in annual ADHD revenue across target territories |EDOMIE PHARMA IN ISRAEL LUPIN IN CANADA mecomie LUPIN iv) InJuly 2023
Slide 23: Financials
Slide 24: Revenue & Adjusted EBITDA
Revenue & Adjusted EBITDA Suspension of clinical development programs began in October 2022 Wind down and divestiture of the Consumer Health business in July 2024 REVENUE* ADJUSTED EBITDA* sn8 ” | a Et =~ 5052 | al q 22 203 22s THM Mar. 2025 2a am 203 202s TMMar 2005, 24 DAVY sratecs coromarse bsns
Slide 25: Favorable Gross Margin & OpEx Trends
Favorable Gross Margin & OpEx Trends Production outsourcing & volume increases have driven Rx business gross margin improvement Efficiencies expected due to additional operational consolidation RGIN* ADJUSTED OP 20% ow 71% 7% 10% cow som aw 40% 20m | 2 40% 20% 10% om om 2m am 2003 2028 TIM Mar 2005:
Slide 26: Balance Sheet Highlights
Balance Sheet Highlights Successfully refinanced previous term loan and extended revolving credit facility on more favorable terms to the Company in June 2024. qUnPecacr ee a/sva025 cash and cash equivalents $18,173 al current assets 72512 Torel current asset bl JUNE 2025 Intangible assets, net $43,
Slide 27: Aytu BioPharma is a Well-Positioned Specialty Pharmaceutical Company
Aytu BioPharma is a Well-Positioned Specialty Pharmaceutical Company Leveraging the unique capabilities of the now streamlined organization to grow commercialized novel prescription therapeutics and drive cash flow and profitability. ®P A ® OW A (creas eerie scree pose | oaperwers flex peers eae ESS
Slide 28: Experienced Management Team
Experienced Management Team ine a db Ampig, Pros ovr arbor =: aa eS arbor UvaNova nao Bion - TECONMED > accenria 2 wwoscance gy enone Tova @ on ZOGENIX ome Gsk GSK — cartoon Zendo 2s OAytu
Slide 29: Appendix
Slide 30: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation $ in thousands section secur a = z z 7 30 @Aytu
Slide 31: EXXUA Summary of Deal Terms
a EXXUA Summary of Deal Terms Fixed Payments: + $3M paid at execution + Additional $3M paid within forty-five (45) days of 1* anniversary of Commercial Launch (as defined) + Second upfront payment increases to $5M if Net Sales (as defined) for the first 12 months > $35M Royalties (% of Net Sales): +
Slide 32: Adjusted OpEx as a % of Net Revenue
Adjusted OpEx as a % of Net Revenue Reconciliation $ in thousands
Slide 33: Capitalization Table
Capitalization Table 19/2025 Shares Outstanding: 8,976,914 Options outstanding: Avg. Strike Price 8 453 219,244 Warrants outstanding: Strike Price __ Expiration Date Tune 2025 Common Warrants - Prefunded s 0.0001 NA 8,233,332 Tune 2023 Common Warrants - Prefunded s 0.0001 NA 2,060,651 Tune 2023 Comm